The duchenne muscular dystrophy (DMD) drugs market is expected to grow at a CAGR of 12.1% during the forecast period of 2024 to 2032, due to advancements in medical research, increased awareness of the disease, and the development of innovative therapeutic approaches. Duchenne Muscular Dystrophy, a severe type of muscular dystrophy, primarily affects boys and leads to progressive muscle degeneration and weakness. The market for DMD drugs is driven by the urgent need for effective treatments that can slow down disease progression, improve the quality of life for patients, and potentially offer a cure.
The cell line development market is expected to grow at a CAGR of 13.3% during the forecast period of 2024 to 2032, due to advancements in biotechnology and an increasing demand for biopharmaceuticals. Cell lines are essential for producing biologics, which include vaccines, therapeutic proteins, and monoclonal antibodies. The cell line development market is poised for significant growth driven by the rising demand for biopharmaceuticals, advancements in cell line development technologies, and increasing investment in research and development.
Medical foods are specially formulated products designed for the dietary management of a disease or condition with unique nutritional needs that cannot be met by a regular diet alone. They are not mere diet foods or traditional supplements. Instead, they address specific dietary deficiencies related to certain diseases or conditions. These products are intended to be consumed or administered under the guidance of a physician. The U.S. Food and Drug Administration (FDA) provides specific criteria that products must meet to be classified as medical foods.
